(Q39030297)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25762000%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

title

A phase I open-labeled, single-arm, dose-escalation, study of dichloroacetate (DCA) in patients with advanced solid tumors (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25762000%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

0 references

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25762000%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

John R. Mackey

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25762000%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

author name string

Quincy Siu-Chung Chu

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25762000%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Randeep Sangha

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25762000%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Jennifer Spratlin

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25762000%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Alexander J B McEwan

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25762000%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Peter Venner

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25762000%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Evangelos D Michelakis

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25762000%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

publication date

13 March 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25762000%20AND%20SRC:MED&resulttype=core&format=json

Investigational New Drugs

2 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25762000%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

volume

33

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25762000%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25762000%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

page(s)

603-610

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25762000%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s10637-015-0221-y

2 March 2020

exact match

0 references

cites work

THE METABOLISM OF TUMORS IN THE BODY

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0221-Y

Understanding the Warburg effect: the metabolic requirements of cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0221-Y

Pyruvate dehydrogenase kinase as a novel therapeutic target in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0221-Y

A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0221-Y

HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0221-Y

Tyrosine phosphorylation of mitochondrial pyruvate dehydrogenase kinase 1 is important for cancer metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0221-Y

Probing the mechanism of inactivation of human pyruvate dehydrogenase by phosphorylation of three sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0221-Y

The HIF pathway in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0221-Y

Activation of tyrosine kinases in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0221-Y

Metabolic modulation of glioblastoma with dichloroacetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0221-Y

Dichloroacetate causes toxic neuropathy in MELAS: a randomized, controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0221-Y

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0221-Y

Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0221-Y

Long-term safety of dichloroacetate in congenital lactic acidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0221-Y

Dichloroacetate causes reversible demyelination in vitro: potential mechanism for its neuropathic effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0221-Y

A phase II, open-label study of ramucirumab in combination with paclitaxel and carboplatin as first-line therapy in patients with stage IIIB/IV non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0221-Y

Phase 1 trial of dichloroacetate (DCA) in adults with recurrent malignant brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0221-Y

Human polymorphisms in the glutathione transferase zeta 1/maleylacetoacetate isomerase gene influence the toxicokinetics of dichloroacetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0221-Y

Inhibition of glutathione S-transferase zeta and tyrosine metabolism by dichloroacetate: a potential unifying mechanism for its altered biotransformation and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0221-Y

Mitochondrial activation by inhibition of PDKII suppresses HIF1a signaling and angiogenesis in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0221-Y

A nuclear pyruvate dehydrogenase complex is important for the generation of acetyl-CoA and histone acetylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0221-Y

Mitaplatin, a potent fusion of cisplatin and the orphan drug dichloroacetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0221-Y

Dichloroacetate should be considered with platinum-based chemotherapy in hypoxic tumors rather than as a single agent in advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0221-Y

Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0221-Y

Synergistic antitumor effect of dichloroacetate in combination with 5-fluorouracil in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0221-Y

Dichloroacetate attenuates hypoxia-induced resistance to 5-fluorouracil in gastric cancer through the regulation of glucose metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0221-Y

Combination of sulindac and dichloroacetate kills cancer cells via oxidative damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0221-Y

Dichloroacetate reverses the hypoxic adaptation to bevacizumab and enhances its antitumor effects in mouse xenografts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0221-Y

Dichloroacetate (DCA) sensitizes both wild-type and over expressing Bcl-2 prostate cancer cells in vitro to radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0221-Y

Pharmacokinetics, metabolism and toxicology of dichloroacetate

21 January 2018

1 reference

12 December 2020

Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer.

1 reference

12 December 2020

Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines

1 reference

12 December 2020

Phase I study of oxaliplatin in patients with advanced cancer

1 reference

12 December 2020

Co-treatment of dichloroacetate, omeprazole and tamoxifen exhibited synergistically antiproliferative effect on malignant tumors: in vivo experiments and a case report

1 reference

12 December 2020

10.1007/S10637-015-0221-Y

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25762000%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

1 reference